SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-276377
Filing Date
2022-11-03
Accepted
2022-11-03 07:17:32
Documents
15
Period of Report
2022-10-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d402248d8k.htm   iXBRL 8-K 29455
2 EX-99.1 d402248dex991.htm EX-99.1 64517
3 EX-99.2 d402248dex992.htm EX-99.2 8748
7 GRAPHIC g402248g59u20.jpg GRAPHIC 3198
  Complete submission text file 0001193125-22-276377.txt   246354

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kymr-20221031.xsd EX-101.SCH 2860
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20221031_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20221031_pre.xml EX-101.PRE 11264
9 EXTRACTED XBRL INSTANCE DOCUMENT d402248d8k_htm.xml XML 3360
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 221356200
SIC: 2836 Biological Products, (No Diagnostic Substances)